iShares High Yield Systematic Bond ETF (BATS: HYDB)

iShares High Yield Systematic Bond ETF (BATS:HYDB), Trade Ideas

iShares High Yield Bond Factor ETF

iShares High Yield Systematic Bond ETF

WIIM

LKQ shares are trading lower after the company reported a Q1 earnings miss and cut its FY24 outlook.

JMP Securities analyst Joe Goodwin reiterates Model N (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODN#NYSE">MODN</a>) with a Market Perform.

News

Reiteration

Analyst Ratings

MODN

JMP Securities Reiterates Market Perform on Model N

Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) has outperformed the market over the past 5 years by 6.52% on an annualized basis producing an average annual return of 17.86%. Currently, Riot Platforms has a market capitalization of $2.99 billion. 
Buying $100 In RIOT: If an investor had bought $100 of RIOT stock 5 years ago, it would be worth $225.23 today based on a price of $11.78 for RIOT at the time of writing.
<h3>Riot Platforms's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713880851_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

RIOT

$100 Invested In Riot Platforms 5 Years Ago Would Be Worth This Much Today

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 13.43% on an annualized basis producing an average annual return of 23.78%. Currently, Meta Platforms has a market capitalization of $1.24 trillion. 
Buying $100 In META: If an investor had bought $100 of META stock 10 years ago, it would be worth $874.40 today based on a price of $490.68 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713880846_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Meta Platforms Stock In The Last 10 Years

Macro Economic Events

Econ #s

Economics

USA New Home Sales (MoM) For March 8.8% Vs -5.1% Prior

In the preceding three months, 4 analysts have released ratings for Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $97.75, a high estimate of $118.00, and a low estimate of $83.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 17.16%. 
<img src="https://www.benzinga.com/files/images/story/2024/1713880831_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Addus HomeCare among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Underweight</td>
<td>$83.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$118.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$102.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Addus HomeCare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Addus HomeCare's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Addus HomeCare's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Addus HomeCare analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Addus HomeCare Better</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>Addus HomeCare: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Addus HomeCare displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 11.86%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.08%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Addus HomeCare's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.81% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Addus HomeCare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.9%, the company showcases efficient use of assets and strong financial health.
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average. With a ratio of 0.25, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADUS

Cracking The Code: Understanding Analyst Reviews For Addus HomeCare

Eastern Bankshares's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBC#NYSE">EBC</a>) short percent of float has risen 3.75% since its last report. The company recently reported that it has 4.84 million shares sold short, which is 2.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Eastern Bankshares Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713880829_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eastern Bankshares has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Eastern Bankshares's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Eastern Bankshares's peer group average for short interest as a percentage of float is 5.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Eastern Bankshares?

Hamilton Lane's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NYSE">HLNE</a>) short percent of float has fallen 11.83% since its last report. The company recently reported that it has 876 thousand shares sold short, which is 2.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Hamilton Lane Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713880823_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hamilton Lane has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Hamilton Lane's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hamilton Lane's peer group average for short interest as a percentage of float is 2.71%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

HLNE

Looking Into Hamilton Lane's Recent Short Interest

Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) has been analyzed by 17 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Five Below, presenting an average target of $211.29, a high estimate of $245.00, and a low estimate of $170.00. Observing a downward trend, the current average is 5.48% lower than the prior average price target of $223.53. 
<img src="https://www.benzinga.com/files/images/story/2024/1713880821_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Five Below by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Chuck Grom</td>
<td>Gordon Haskett</td>
<td>Lowers</td>
<td>Accumulate</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$214.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$204.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Jeremy Hamblin</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Hold</td>
<td>$187.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$245.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>George Kelly</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Matthew Korn</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>David Bellinger</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Buy</td>
<td>$225.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$230.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Nagel</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Perform</td>
<td>$200.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Matthew Korn</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$222.00</td>
<td>$217.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Five Below. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Five Below compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Five Below's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Five Below's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FIVE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Five Below analyst ratings.</a>
<h2>Unveiling the Story Behind Five Below</h2>
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise.
<h3>Five Below's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Five Below's revenue growth over a period of 3 months has been noteworthy. As of 31 January, 2024, the company achieved a revenue growth rate of approximately 19.15%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Five Below's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.12%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Five Below's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 13.65%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Five Below's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 5.37%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.1, Five Below adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FIVE

The Analyst Landscape: 17 Takes On Five Below

USA New Home Sales For March 693K Vs 668K Est.; 637K Prior

First American Financial's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FAF#NYSE">FAF</a>) short percent of float has fallen 34.83% since its last report. The company recently reported that it has 1.16 million shares sold short, which is 1.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>First American Financial Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713880818_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for First American Financial has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing First American Financial's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, First American Financial's peer group average for short interest as a percentage of float is 1.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(FAF) - Analyzing First American Financial's Short Interest

Keybanc analyst Sophie Karp downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Overweight to Sector Weight.

Downgrades

NOVA

Keybanc Downgrades Sunnova Energy Intl to Sector Weight

Shares of life sciences tools stocks are trading higher following strong earnings from Danaher.

Loop Capital analyst Yun Kim downgrades Matterport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTTR#NASDAQ">MTTR</a>) from Buy to Hold and raises the price target from $5 to $5.5.

Price Target

MTTR

Loop Capital Downgrades Matterport to Hold, Raises Price Target to $5.5

RNAC

Cartesian Therapeutics shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.

https://www.reuters.com/business/autos-transportation/tesla-aims-cut-400-jobs-germany-via-voluntary-programme-2024-04-23/#:~:text=FRANKFURT%2C%20April%2023%20(Reuters),programme%20instead%20of%20forced%20layoffs.

TSLA

'Tesla aims to cut 400 jobs in Germany via voluntary program' -Reuters

Halliburton Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) reported&nbsp;first-quarter 2024 revenue growth&nbsp;of 2.2% year-over-year to $5.804 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38374599/halliburton-announces-first-quarter-2024-results" rel="noreferrer noopener">beating the consensus of $5.668 billion.</a>
Completion and Production revenue was $3.4 billion, slightly down from 2023. Operating income rose 3% to $688 million, fueled by diverse global service improvements and higher product sales.
Drilling and Evaluation revenue rose 7% to $2.4 billion, with operating income up 8% at $398 million, driven by increased drilling services in the Middle East and North America despite some regional drops.
HAL&#8217;s North&nbsp;America&nbsp;revenue fell 8% to $2.5 billion due to decreased U.S. pressure pumping and regional wireline activity.
International revenue was $3.3 billion, an increase of 12% YoY, with revenue from Latin America +21%, Europe/Africa +10% and Middle East/Asia +6%.
Total operating income rose 1% to $987 million, and margin contracted by 20 bps to 17%.
The company repurchased ~$250 million of its common stock during the quarter.
Adjusted EPS was $0.76,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $0.74.</a>
Operating cash flow stood at $487 million for the quarter compared to $122 million a year ago, and free cash flow was $206 million.
&#8220;Activity in North America recovered from fourth-quarter lows, and our international business delivered its 11th consecutive quarter of year-on-year growth. Our customers&#8217; multi-year activity plans across markets and asset types confirms my confidence in the strength and duration of this upcycle,&#8221; commented Jeff Miller, Chairman, President, and CEO.
In its conference call, Halliburton said it expects 2024 revenue growth in the low double digits.
Price Action: HAL shares are trading lower by 0.10% at $38.68 at the last check Tuesday.
Photo via Wikimedia Commons

Earnings

Guidance

Halliburton's Strong International Performance Lifts Q1 Revenue Amid North American Challenges

VLRS

Controladora Vuela shares are trading higher after the company reported better-than-expected Q1 financial results.

Monday, the FDA approved&nbsp;ImmunityBio Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) Anktiva (N-803, or&nbsp;nogapendekin&nbsp;alfa&nbsp;inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS),&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38368486/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresp" rel="noreferrer noopener">with or without papillary tumors</a>.
The drug is combined with the BCG vaccine, mainly used against tuberculosis and as a&nbsp;common&nbsp;treatment for some forms of bladder cancer.
Last year in May, the FDA issued a complete response letter to&nbsp;Anktiva plus BCG treatment, citing deficiencies related to the FDA&#8217;s pre-license inspection of the company&#8217;s third-party&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/05/32341596/stock-loses-50-in-one-trading-session-why-are-immunitybio-shares-tanking-today" rel="noreferrer noopener">contract manufacturing organizations</a>.
&#8220;The FDA&#8217;s approval of ANKTIVA marks our launch of a next-generation immunotherapy beyond checkpoint inhibitors,&#8221; said Patrick Soon-Shiong, Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio.&nbsp;
The company says Anktiva is a first-in-class IL-15 agonist immunotherapy for NMIBC and received FDA Breakthrough Therapy Designation and approval based on the safety and efficacy outcome of complete responses (CR) and duration of complete response (DOR).&nbsp;
The CR rate for the 77 evaluable patients was 62%, with the upper end of the confidence interval being 73%.&nbsp;
The duration of the complete response as of the November 2023 cut-off was more than 47 months and is ongoing to date.&nbsp;
The company adds that the prolonged duration of complete response results beyond 24 months with ANKTIVA and BCG&nbsp;exceeds the benchmark&nbsp;for the magnitude of meaningful clinical results suggested by a panel of experts at the IBCG.
The duration of response is ongoing, so the final median duration of response has yet to be determined. 58% of patients with CR had a DOR ≥ 12 months, and 40% had a DOR ≥ 24 months.
Anktiva is expected to be available in the U.S. by mid-May 2024.
Price Action:&nbsp;IBRX shares are up 4.65% at $5.17 at the last check Tuesday.

Biotech

Health Care

Movers

General

IBRX

FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies

Jack Fox, the Pro Bowl punter for the Detroit Lions and upcoming speaker at <a href="https://www.benzinga.com/nfldraft/" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s 2024 Detriot Draft</a> event, epitomizes the perseverance and excellence of professional sports. 
Transitioning from an undrafted player in 2019 to becoming the league&#8217;s highest-paid punter, Fox&#8217;s journey underscores his commitment and prowess on the field. 
Initially signing briefly with the Kansas City Chiefs, Fox found his stride with the Lions, where he was quickly recognized for his powerful punting, securing a Pro Bowl selection shortly after his debut season.
<h3 class="wp-block-heading">Strategic Contract Renewal</h3>
In 2022, Fox reinforced his value to the Lions through a three-year contract extension valued at $11.325 million, highlighting his integral role on the team. His exceptional ability to maintain an average of 49.1 yards per punt has been critical in setting team records and establishing him as a dependable player during strategic plays, including booming fake punts​.
<h3 class="wp-block-heading">Commitment to Craft and Community</h3>
Fox&#8217;s dedication extends beyond the playing field. He trains intensively in Alabama each offseason to enhance his athletic performance for forthcoming seasons. His community involvement is also notable; he organizes and leads camps for aspiring young punters and kickers in the Detroit area, demonstrating his commitment to developing the next generation of athletes.
<h3 class="wp-block-heading">Why You Should Attend Benzinga&#8217;s Draft Event</h3>
Benzinga is a leader in the events space. It has the experience to connect its audience with speakers, panelists, and other attendees. The financial media company has organized 32 &#8216;Business Titans&#8217; events and is known globally for its popular, high-profile gatherings.
The Benzinga Sports Business Titans event features a strong lineup of speakers from the sports and business worlds. Each guest will share their journeys of entrepreneurship and investments.
Athletes, social media stars, and business leaders will share advice and provide a behind-the-scenes look at how sports and business often intersect. This event features former and current athletes and critical business voices. Join Benzinga for the 2024 Sports Business Titans.&nbsp;<a href="https://www.benzinga.com/nfldraft/" target="_blank" rel="noreferrer noopener">Get tickets here</a>.
Image: Football.Shutterstock

Sports

Events

Star Detroit Lions Punter To Speak At Benzinga's Detroit Draft Event

Junk Bond Default Surge Continues In 2024

Credit Maturity Wall: Not As Difficult A Climb As It May Seem

iShares High Yield Bond Factor ETF declares monthly distribution of $0.3263

Fixed-Income Outlook: Don't Miss The Forest For The Trees

IShares Spring 2024 Investment Directions

TDAM CIO On Navigating The Markets After Strong Start To The First Quarter

Fixed Income: No Time To Yield

Fixed Income Perspectives - Looking Ahead At Q2 2024: A Pause Before A Pivot

Fixed Income Investment Outlook Q2 2024: A Winding, Downward Path

Bubble Up: The Everything, Everywhere Bubble

AAAU

ACTV

AEMB

AFMC

AFSM

ANEW

ANGL

ARKK

ARKQ

AVMU

AVUV

AYTEF

BAPR

BBCA

BBCB

BBHY

BGLD

BGRN

BINC

BKHY

BNDX

BOTZ

BSJN

BSJO

BSJP

BSJQ

BSJR

BSJS

BSJT

BSMN

BSMO

BSMP

BSMQ

BSMR

BSMS

BSMT

CBON

CEMB

CLOI

CLRG

CMBS

CORP

COWZ

DDIV

DEED

DEUS

DFHY

DGRO

DIVB

DRSK

DTEC

DVLU

DYNF

EBND

EDOW

EFIX

EMBD

EMCB

EMHC

EMHY

EMLC

EMTL

EMXC

EQRR

ESGS

ESHY

FAIL

FALN

FCAL

FCOR

FDHY

FDRR

FDVV

FEMB

FFSM

FIBR

FLCA

FLCO

FLHY

FLIA

FLMB

FLMI

FLQM

FMHI

FMNY

FNDB

FNDX

FOVL

FREL

FSMB

FTDS

FUMB

FVAL

GBIL

GHYB

GHYG

GIGB

GLDI

GLDM

GLTR

GOVT

GOVZ

HEEM

HMOP

HOMZ

HYBB

HYDB

HYDW

HYEM

HYGH

HYGV

HYLB

HYLS

HYMB

HYMU

HYUP

HYXF

HYXU

IAUF

IAUM